Clinical Research Directory

Inclusion Criteria: * ≧18 years old, ≦80 years old; * Acute phase with a course of disease ≦14 days; * CTA confirmed diagnosis of active dissection type B in accordance with the Stanford classification in the ESC guidelines, and requiring TEVAR surgery; * For patients with acute non-type A and non-type B aortic dissection involving the left subclavian artery: current technologies (such as fenestration, single branch, chimney, etc.) can be used to solve the reconstruction of the left subclavian artery; * The distal end of the dissection exceeds the renal artery plane; * Signed informed consent (emergency waiver applicable), with primary intervention using CTAG devices. Adjunctive procedures may include LSA revascularization, percutaneous fenestration, aortic/peripheral stenting, surgical fenestration, or bypass grafting. * Medical record completeness \>90% with mandatory CTA data; * Protocol compliance including follow-up adherence Exclusion Criteria: * Dissection termination above renal arteries; * Major aortic surgery within 30 days prior (except LSA revascularization); * Iliofemoral stenosis/angulation precluding endovascular access; * Non-diagnostic CTA image quality; * Indeterminate symptom onset time; * Traumatic TBAD, intramural hematoma, or penetrating aortic ulcer; * Complete thoracic aortic thrombosis pre-TEVAR; * Re-intervention within 12 months post-TEVAR for non-aortic indications; * Renal failure: Baseline serum creatinine \>2.5 mg/dL (high-risk for contrast nephropathy); * Known device material hypersensitivity; * Systemic infection increasing endograft infection risk; * Evidence of aortic infection; * Connective tissue disorders (e.g., Marfan syndrome); * Bowel necrosis from visceral ischemia; * Participation in other device/drug trials within 1 year; * Moribund status: ASA class 5 with \<24h life expectancy; * Refractory shock (SBP \<90 mmHg); * Pregnancy or lactation; * Active substance abuse.